Arbutus Biopharma ABUS
NASDAQ ABUS
$4.18 -0.15 (-3.46%)
At close: Oct 21, 2026 · 4:00 PM EDT

Arbutus Biopharma (ABUS) Cash from Restructuring (2018 - 2025)

Updated

Arbutus Biopharma (ABUS) reported Cash from Restructuring of -$66,000 for Q4 2019, compared with $561,000 a year earlier.

Analysis

Arbutus Biopharma (ABUS) Cash from Restructuring (2018 - 2025) Analysis & Trends

For FY2019, Arbutus Biopharma posted Cash from Restructuring of -$983,000.

  • By year, Cash from Restructuring came in at $1.33 million in FY2018.
  • Five-year quarterly Cash from Restructuring spans a low of -$640,000 in Q2 2019 and a high of $1.03 million in Q1 2018.
  • Per Business Quant data, the three quarters before Q4 2019 came in at -$138,000 (Q3 2019), -$640,000 (Q2 2019) and -$139,000 (Q1 2019).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn
10 Arbutus Biopharma 826.41 Mn 453.39 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2025 2.81 Mn
Sep 30, 2024 167,000.00
Dec 31, 2019 -66,000.00
Sep 30, 2019 -138,000.00
Jun 30, 2019 -640,000.00
Mar 31, 2019 -139,000.00
Dec 31, 2018 561,000.00
Sep 30, 2018 -320,000.00
Jun 30, 2018 395,000.00
Mar 31, 2018 1.03 Mn
API Access

Arbutus Biopharma Cash from Restructuring API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=cash-from-restructuring&ticker=ABUS&period=max&api_key=YOUR_API_KEY